Skip to content
Peptide Evidence RegistryFollow the evidence

GLP-1s & incretins · Metabolic & endocrine

Petrelintide

A long-acting amylin analogue in Phase 2, with Phase 3 weight-management trials planned.

L3Early human studiesIn clinical trialsIn clinical development
How settled this rating is:
low confidence in the current evidence rating
Routes studied:
Subcutaneous injection
Also known as:
long-acting amylin analogue, ZP8396
Last reviewed:
2026-09-06
Jump to section

Evidence passport

Last reviewed 2026-09-06

A one-screen summary of what is known about this compound. Every field describes the evidence and legal status — not how safe or effective it is, and not a recommendation. The 0-100 figures are evidence-strength ratings, not percentages.

Evidence level (type of study, not a quality rating)
L3Early human studies
How settled this rating is
Low confidence in rating
Human efficacy evidence
38 of 100 evidence strength
Human safety evidence
22 of 100 evidence strength
Regulatory status
In clinical trials
Development
In clinical development
Routes
SC injection
Evidence base
Includes human studies
Furthest stage
Phase II
Source curation
Sources fully curated
How far human research has progressed
Phase 2 programme reported; Phase 3 initiation planned

Overview

Human efficacy evidence strength38 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Preclinical (animal / lab) evidence strength62 of 100 evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Human safety evidence strength22 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

How far human research has progressed: Phase 2 programme reported; Phase 3 initiation planned

Routes & formulations

Studied / approved routes

SC injection

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

    Furthest established stage

  5. Phase III

  6. Approved

In clinical development

Active development. Phase 2 (ZUPREME) reported by the sponsor; Phase 3 chronic weight management initiation described as planned for H2 2026.

Last documented development: 2026 — Phase 2 reported, Phase 3 planned

What it is

A long-acting synthetic amylin analogue intended for weekly subcutaneous use, positioned as an alternative or partner to incretin therapy rather than a replacement for it.

What people claim

  • Meaningful weight loss with amylin pharmacology alone
  • Better tolerability than incretins

What the evidence actually says

Mid-stage sponsor-reported data exist and a Phase 3 programme is planned, which puts this ahead of most of the registry — but well behind the approved incretins. Tolerability comparisons in particular are marketing-adjacent until head-to-head trials say otherwise.

Related evidence

Useful next reads based on this compound — not recommendations.

Human evidence

  • Sponsor-reported Phase 2 ZUPREME programme results in overweight and obesity.
  • Phase 3 chronic weight management programme described as planned for H2 2026.

Preclinical evidence

  • Amylin analogue pharmacology and rodent food-intake models.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • Amylin and calcitonin receptor signalling reduces meal size and slows gastric emptying.

Safety and unknowns

  • Gastrointestinal effects and injection-site reactions reported in trials.
  • No long-term safety dataset exists.

Cancer relevance

This section covers questions raised by how the compound works in the body, plus anything regulators and trial teams keep an eye on. It is not a statement that this compound causes cancer — for most compounds here, no human data exist in either direction.

No established human signal

No established human cancer signal for this compound.

Regulatory status

Not approved anywhere. The sponsor's Phase 2 ZUPREME programme has reported results, and initiation of Phase 3 chronic weight management trials was described as planned for the second half of 2026.

Evidence grade

L3Early human studiesLow confidence in rating

Small, short or uncontrolled studies in people. A hint worth following up, not a conclusion you can rely on.

What would change our rating?

  • Peer-reviewed Phase 2 publication.
  • Phase 3 readouts.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

These entries record changes to our assessment of the published evidence — not changes to the compound itself.

No recorded changes yet. Baseline position set on 2026-09-06.